The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Gilead and Merck announced mixed clinical trial results, discontinuing a Phase 3 study for non-small cell lung cancer due to disappointing outcomes. Conversely, the companies reported that Phase 3 trials for a once-weekly oral HIV treatment regimen met their primary efficacy endpoints with a safety profile comparable to existing treatments. Plans are underway to submit this data to global regulatory authorities and present detailed findings at an upcoming scientific congress.